B. Riley Securities Initiates Coverage On Veradermics with Buy Rating, Announces Price Target of $170

Benzinga Newsdesk www.benzinga.com Positive 54.9%

Neg 0% Neu 0% Pos 54.9%

B. Riley Securities analyst Mayank Mamtani initiates coverage on Veradermics (NYSE:MANE) with a Buy rating and announces Price Target of $170.